Analysts’ Upgrades for August, 30th (CAE, CHRW, CIEN, DM, LSTR, MDC, MURGY, PSEC, PTEN, RVNC)

Analysts’ upgrades for Wednesday, August 30th:

CAE (NYSE:CAE) (TSE:CAE) was upgraded by analysts at BMO Capital Markets from a market perform rating to an outperform rating. They currently have $23.00 target price on the stock. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

C.H. Robinson Worldwide (NASDAQ:CHRW) was upgraded by analysts at Stephens from an equal weight rating to an overweight rating. The firm currently has $90.00 price target on the stock, up from their previous price target of $73.00.

Ciena Corporation (NYSE:CIEN) was upgraded by analysts at Citigroup Inc. from a neutral rating to a buy rating.

Dominion Midstream Partners, (NYSE:DM) was upgraded by analysts at Morgan Stanley from an equal weight rating to an overweight rating.

Landstar System (NASDAQ:LSTR) was upgraded by analysts at Stephens from an equal weight rating to an overweight rating. Stephens currently has $103.00 target price on the stock, up from their previous target price of $88.00.

M.D.C. Holdings (NYSE:MDC) was upgraded by analysts at Wells Fargo & Company from an underperform rating to a market perform rating. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Muenchener Rckvrrgs Gsllcht Mhn AG (NASDAQ:MURGY) was upgraded by analysts at Jefferies Group LLC from a hold rating to a buy rating.

Prospect Capital Corporation (NASDAQ:PSEC) was upgraded by analysts at UBS AG from an underperform rating to a market perform rating.

Patterson-UTI Energy (NASDAQ:PTEN) was upgraded by analysts at Citigroup Inc. from a neutral rating to a buy rating.

Revance Therapeutics (NASDAQ:RVNC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $26.00 price target on the stock. According to Zacks, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. “

Banco Santander, (NYSE:SAN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Banco Santander SA is the biggest bank in Spain and the biggest international bank in Latin America as well. The Bank concentrates its activities in Andalucia, Castilla-Leon, Catalonia, Madrid, Valencia and Cantabria. The Bank provides banking services for individuals and companies, leasing, factoring, stockbrokerage and mutual fund services. “

Swisscom AG (OTCMKTS:SCMWY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $56.00 target price on the stock. According to Zacks, “Swisscom is Switzerland’s leading telecommunications company. The innovative, customer-focused and strongly-competitive group offers a full range of voice and data communication services on fixed-line and mobile networks. Swisscom offers the complete spectrum of state-of-the-art data services, from leased lines to integrated solutions for corporate customers. “

Sage Group Unspon (NASDAQ:SGPYY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “The Sage Group plc supplies business management software, services and support to small and medium sized businesses. The Company’s products includes accounting, payroll, customer relationship management, financial forecasting, payment processing, job costing, human resources, business intelligence, taxation and other products for accountants, business stationery, development platforms, e-business and enterprise resource planning. Sage Group’s products find its application in the healthcare, human resource and payroll, construction/real estate, transport/distribution, payment processing, accountancy, manufacturing, retail, and automotive distribution industries. The products offered by the Company are majorly developed and supported locally. The Sage Group plc is headquartered in Newcastle upon Tyne, the United Kingdom. “

Summit Financial Group (NASDAQ:SMMF) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $24.00 price target on the stock. According to Zacks, “Summit Financial Group operates thirteen banking locations through its three wholly owned subsidiary banks, Summit Community Bank headquartered in Moorefield, West Virginia, Capital State Bank, Inc. headquartered in Charleston, West Virginia, and Shenandoah Valley National Bank in Winchester, Virginia. Summit also operates Summit Financial, LLC, a residential mortgage loan originator located in Herndon, Virginia. “

Sanofi (NYSE:SNY) was upgraded by analysts at HSBC Holdings plc from a reduce rating to a hold rating.